Cover Page

Cite item


Increasing distance between practical public health services and collecting of theoretical information in the field of biomedical researches reflects the necessity of professional contact between clinicians and scientists in many areas associated with medicine for active carrying over («translation») of the modern basic researches in which mechanisms of basic metabolic processes and possibilities of their correction are detected, to effective medical help to individual patient, i.e. personified medicine. Such approach was called transmitting medicine. Examples of the personified medicine in which biomedical researches together with the anamnesis morbi of individual patient that are responsible for treatment strategy including doses and regimens are discussed.


About the authors

O. M. Ipatova

Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow

Author for correspondence.
доктор биологических наук, руководитель отдела нанолекарств ФГБУ «Научно- исследовательский институт биомедицинской химии им. В.Н. Ореховича» РАМН Адрес: 119121, Москва, ул. Погодинская, д. 10 Тел.: 8 (499) 246-94-91 Факс: 8 (499) 245-08-57 Russian Federation

N. V. Medvedeva

Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow

ведущий научный сотрудник лаборатории фосфолипидных нанолекарств и транс- портных систем ФГБУ «Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича» РАМН Адрес: 119121, Москва, ул. Погодинская, д. 10 Тел.: 8 (495) 708-38-07 Russian Federation

A. I. Archakov

Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow

доктор биологических наук, профессор, вице-президент РАМН, академик РАМН, директор института ФГБУ «Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича» РАМН Адрес: 119121, Москва, ул. Погодинская, д. 10 Тел.: 8 (499) 246-69-80 Факс: 8 (499) 245-08-57 Russian Federation

A. I. Grigor'ev

State science center of the Russian Federation, Institute of medical and biologic problems of Russian Academy of Sciences, Moscow

академик РАН и РАМН, вице-президент РАН, научный руководитель Института медико-биологических проблем РАН Адрес: 123007, Москва, Хорошевское шоссе, д. 76 А Факс: 8 (499) 195-22-53 Russian Federation


  1. Marincola F.M. Translational medicine: a two-way road. J. Transl. Med. 2003; 1: 1–2.
  2. Burke J.D., Pincus H.A., Pardes H. The clinician-researcher in psychiatry. Am. J. Psychiatry. 1986; 143: 968–975.
  3. Aronson J.K., Cohen A., Lewis L.D. Clinical pharmacology — providing tools and expertise for translational medicine. Brit. J. Clin. Pharmacol. 2008; 65 (2): 154–157.
  4. Littman B.H., Di Mario L., Plebani M., Marincola F.M. What’s next in translational medicine? Clin. Sci. (Lond). 2007; 112 (4): 217–227.
  5. Ponomareva O.V. Translyacionnye issledovaniya i `evolyuciya podhodov k lecheniyu bol’nyh rakom molochnoj zhelezy. Onkologiya. 2010; 12 (4): 369--376.
  6. Wang X., Wang E., Marincola F.M. Translational Medicine is developing in China: a new venue for collaboration. J. Transl. Med. 2011; 9: 3–5.
  7. Limbert C. Translational medicine: is this a matter for the clinician? Acta Reumatol. Port. 2010; 35 (2): 132.
  8. Day M., Rutkowski J.L., Feuerstein G.Z. Translational medicine — a paradigm shift in modern drug discovery and development: the role of biomarkers. Adv. Exp. Med. Biol. 2009; 655: 1–12.
  9. Clayton T.A., Lindon J.C., Cloarec O. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006; 440 (7087): 1073–1077.
  10. Sarkar I.N. Biomedical informatics and translational medicine. J. Transl. Med. 2010; 8: 22–34.
  11. Archakov A.I., Lisica. A.V., Petushkova N.A., Karuzina I.I. Citohromy R-450, lekarstvennaya bolezn’ i personificirovannaya medicina. Chast’ 1. Klinicheskaya medicina 2008; 86 (2): 4-8.
  12. Medvedeva N.V., Ipatova O.M., Ivanov Yu.D., Archakov A.I. Nanobiotehnologii v medicine. Biomed. himiya. 2006; 52 (6): 529-546.
  13. Jain K.K. Role of nanotechnology in the development of personalized medicine. Nanomedicine. 2009; 4 (3): 249–252.
  14. Kang Ju-S., Lee M.-H. Overview of Therapeutic Drug Monitoring. Korean J. Int. Med. 2009; 24 (1): 1–10.
  15. Thomson A. Why do therapeutic drug monitoring. Pharm. J. 2004; 273: 153–155.
  16. Marshall W.J., Bangert S.K. Clinical Chemistry, 6th Edition. Edinburgh, London: Mosby. 2008. ISBN 9780723434559.
  17. Prikaz Minzdrava RF ot 21 fevralya 2000 g. № 64. http://www. 1&Itemid=24
  18. Andreeva O.V. Primenenie terapevticheskogo lekarstvennogo monitoringa finlepsina v krovi v klinicheskoj praktike. Klin. farmakokin. 2005; 1 (2): 29-33.
  19. Kukes V.G., Bogoslovskaya S.I., Andreev D.A. i dr. Farmakogeneticheskie issledovaniya sistemy biotransformacii i transporterov dlya personalizacii farmakoterapii v kardiologii (rossijskij opyt). Soobschenie vtoroe: farmakogeneticheskie issledovaniya CYP2D6. Klin. farm. terap. 2007; 4: 62-66.
  20. Kukes V., Novikov A., Savchenko A. i dr. Ocenka aktivnosti izofermenta citohroma r450 3a4 (cyp3a4) kak real’naya vozmozhnost’ personalizacii farmakoterapii. Vrach. 2008; 3: 13-19.
  21. Benet L.Z., Kroetz D.L., Sheiner L.B. The dynamics of drug absorption, distribution and elimination. In: The Pharmacologial Basis of Therapeutics. 9th Ed. Chapter I. Goodman & Gillman’s. McGrawHill. 1996. 3–27.
  22. Archakov A.I., Lisica A.V., Petushkova N.A., Karuzina I.I. Citohromy R-450, lekarstvennaya bolezn’ i personificirovannaya medicina. Chast’ 2. Terapevticheskij lekarstvennyj monitoring kak metod ocenki aktivnosti monooksigenaznoj sistemy. Klinicheskaya medicina. 2008; 86 (3): 4-7.
  23. Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J. Oncol. Pharm. Pract. 2007; 13 (4): 207–221.
  24. Christensen J., Hojskov C.S., Poulsen J.H. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay. Ther. Drug Monit. 2002; 24: 658–664.
  25. Christian U., Jacobsen W., Sercova N. et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatographymass spectrometry with on-line extraction: immunosuppressants. J. Chromatography B. Biomed. Sci. Appl. 2000; 748 (1): 41–53.
  26. Liu H., Delgado M.R. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin. Pharmacokinet. 1999; 36: 453–470.
  27. Corona G., Casetta B., Sandron S., Vaccher E., Toffoli G. Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography /tandem mass spectrometry. Rapid Com in Mass Spectrometry. 2008; 22: 519–525.
  28. Zhang D., Liu H., Zhang S. et al. An effective method for de novo peptide sequencing based on phosphorylation strategy and mass spectrometry. Talanta. 2011; 84 (3): 614–622.
  29. Egge-Jacobsen W., Unger M., Niemann C.U., et al. Automated, fast, and sensitive quantification of drugs in human plasma by LC/ LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther. Drug Monit. 2004; 26: 546–562.
  30. Futreal P. A., Coin L., Marshall M. et al. A census of human cancer genes. Nat. Rev. Cancer. 2004; 4 (3): 177–183.
  31. Forbes S.A., Bhamra G., Bamford S., et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. 2008; Chapt. 10: Un. 10.11.
  32. Suh K.S., Park S.W., Castro A. et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert. Rev. Mol. Diagn. 2010; 10 (8): 1069–1083.
  33. Darcy K.M., Birrer M.J. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol. Oncol. 2010; 117 (3): 429–439.
  34. Diaz-Rubio E. Translational research in clinical oncology: challenges and opportunities. Farm. Hosp. 2010; 34S1: 1–7.
  35. Strimpakos A.S., Syrigos K.N., Saif M.W. Translational research in pancreatic cancer. Highlights from the «2010 ASCO Gastrointestinal Cancers Symposium». Orlando, FL, USA. January 22–24, 2010. JOP. 2010; 11 (2): 124–127.
  36. Strimpakos A.S., Syrigos K.N., Saif M.W. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut. Liver. 2010; 4 (4): 433–449.
  37. Chung H-W., Lee S-G., Kim H. et al. Serum high mobility group box-1 (HMGB1) is closely associated with clinical and pathological features of gastric cancer. J. Transl. Med. 2009; 7: 38–48.
  38. Albin R.J., Marincola F.M., Natali P.G. The «Excellence in Translational Medicine» and «Bedside-to-Bench» Awards 2008–2009. J. Transl. Med. 2010; 8: 95–96.
  39. Li K.M., Rivory L.P., Hoskins J. et al. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Brit. J. Clin. Pharmacol. 2007; 63 (1): 67–74.
  40. Johnson K.A., Brown P.H. Drug development for cancer chemoprevention: focus on molecular targets. Semin. Oncol. 2010; 37 (4): 345–358.
  41. Delaney A., Fleetwood S.M., Colvin L.A., Fallon M. Translational medicine: cancer pain mechanisms and management. Brit. J. Anaest. 2008; 101 (1): 87–94.
  42. Eschenhagen T., Force T., Ewer M.S. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011; 13 (1): 1–10.
  43. Gonzalez A., Lopez B., Beaumont J. et al. Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. Rev. Esp. Cardiol. 2009; 62 (3): 305–313.
  44. Heidecker B., Kasper E.K., Wittstein I.S. et al. Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation. 2008; 118: 238–246.
  45. McNamara D.M. Pharmacogenomics for neurohormonal intervention in heart failure. Cardiol. Clin. 2008; 26: 127–135.
  46. Berhane B.T., Zong C., Liem D.A. et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics. 2005; 5: 3520–3530.
  47. Dunn W.B., Broadhurst D.I., Deepak S.M. et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics. 2007; 3: 413–426.
  48. Campuzano O., Sarquella-Brugada G., Brugada R. et al. Cardiovascular translational medicine (IV): The genetic basis of malignant arrhythmias and cardiomyopathies. Rev. Esp. Cardiol. 2009; 62 (4): 422–436.
  49. Donahue J.K. Gene therapy for cardiac arrhythmias: A dream soon to come true? J. Cardiovasc. Electrophysiol. 2007; 18: 553–559.
  50. Feldman A.M., Koch W.J., Force T.L. Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Clin. Pharmacol. Ther. 2007; 81 (6): 887–892.
  51. Feuerstein G.Z., Ruffolo R.R. Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective. Expert Opin. Investig. Drugs. 2007; 16 (9): 1315–1326.
  52. Salzberg D.J., Weir M.R. COX-2 inhibitors and cardiovascular risk. Subcell Biochem. 2007; 42: 159–174.
  53. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116 (1): 4–15.
  54. Krishnan A., Yadav K., Kaur M., Kumar R. Epidemiology to public health intervention for preventing cardiovascular diseases: the role of translational research. Indian J. Med. Res. 2010; 132 (5): 643–650.

Comments on this article

Copyright (c) 2012 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies